We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovati
The WHO reports that in 2015, cancer was the second highest cause of death globally – responsible for 8.8 million fatalities, yet we are at a point in time where the speed of advancement in underst
On August 12 of this year the US senate unanimously passed the Race to Accelerate Cures and Equity for Children Act (RACE) expanding on the already enacted Pediatric Research Equity Act (P
IQVIA’s Murray Aitken examines the potential for savings from a new wave of oncology biosimilars – but says payers have to invest in education and incentives to maximise uptake.